

To: [REDACTED] 5.1.2e [REDACTED] 5.1.2e @rivm.nl]
From: [REDACTED] 5.1.2e @ [REDACTED]
Sent: Tue 12/22/2020 8:40:56 PM
Subject: Virus variants and vaccines
Received: Tue 12/22/2020 8:41:06 PM

Dear [REDACTED] 5.1.2e

Although I do imagine you are busy, I wanted to contact you as I got your contact from [REDACTED] 5.1.2e. As you probably know we are working here at Janssen on developing a COVID19 vaccine and are currently in phase 3 trials that hopefully will give us an efficacy signal soon. One of the key question is if a vaccine inducing a polyclonal response would protect against all currently circulating SARS-CoV-2 variants or future ones. This is a question that will be relevant for the foreseeable future. We are already answering this question, however for the future it would be good to understand if there is a way you (or RIVM) could help us in answering these questions.

The assays we are currently using are [REDACTED] 5.1.1c. Especially for the latter it would be great if there is a way to share newly emerging viruses or/and work on the assay together. Let me know if this would be something you could help and if you have time for a quick call.

Best and happy holidays!

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e

Janssen Infectious Diseases & Vaccines TA



Janssen Vaccines & Prevention B.V.

Archimedesweg 4-6

2333 CN Leiden

The Netherlands

mobile: +31 [REDACTED] 5.1.2e

phone: +31 [REDACTED] 5.1.2e

[REDACTED] 5.1.2e [@its.jnj.com](mailto:[REDACTED]@its.jnj.com)